Ms. Katherine Ranile, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2277 Dakota Sky Ct, Henderson, NV 89052 Phone: 702-539-1163 |
Kelly Lizbeth Garcia, MS OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2831 Saint Rose Pkwy Ste 334, Henderson, NV 89052 Phone: 702-589-4630 |
Madeline Dunlap Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 2496 Devotion Ridge Dr, Henderson, NV 89052 Phone: 501-258-1983 |
News Archive
To increase COVID-19 vaccination rates, public health officials must understand who is refusing the vaccines. New research led by Ben Goldacre from the University of Oxford found that about 2% of people considered high-risk did not want the vaccine when offered. In addition, vaccination refusal in priority groups was most common among English people who are Black, South Asian, or from lower socioeconomic areas.
Youths with type 1 diabetes, especially boys, already show early signs of cardiovascular disease by their teen-age years, according to researchers from the Keck School of Medicine of the University of Southern California and Childrens Hospital Los Angeles.
MedAptus(R), the market leader for charge capture technologies, today announced that providers across multiple specialties at Jordan Physician Associates, located in Plymouth, Massachusetts, are using the MedAptus Inpatient Edition to capture and submit professional charges while on service at Jordan Hospital.
Pathway Medical Technologies, Inc., an innovator of endovascular treatments for peripheral vascular disease (PVD), today announced enrollment of the first patient in the company's JETSTREAM G3 Calcium Study, a prospective, single-arm, multi-center registry to evaluate the treatment effects of the JETSTREAM G3 System in patients with moderate to severely calcified peripheral artery disease.
Researchers at Mount Sinai School of Medicine have found in a Phase II trial that a gene therapy developed at Mount Sinai stabilized or improved cardiac function in people with severe heart failure. Patients receiving a high dose of the therapy, called SERCA2a, experienced substantial clinical benefit and significantly reduced cardiovascular hospitalizations, addressing a critical unmet need in this population.
› Verified 9 days ago